Membranous nephropathy associated with multicentric Castleman’s disease that was successfully treated with tocilizumab: a case report and review of the literature

Table 3 Summary of the outcomes of the reported cases

	Article	LN	Renal phenotype	Renal histological type	Treatment	Renal outcomes	Patient outcomes
1	Weisenburger 1979	NA	NS	MN	Symptomatic treatment	NA	NA
2	Ruggieri 1990	HV	NS	MN	Lymphadenectomy, CY, Indomethacin	Complete remission	Survive
3	Komaba 2008 pat 1	Mixed	Mild proteinuria	MN (IgG2 positive),Localized IN	PSL, TCZ	Proteinuria < 0.5 g/day	Survive
4	Tazi 2012	HV	NS	MN	PSL	Complete remission	Survive
5	Xu 2012 pat 15	PC	Hematuria, NS, ARF, RPGN	CG, MN	R-CHOP, HD, PE	Chronic renal failure	Survive
6	Sun 2020 pat 12	NA	NA	ATIN, MN	PSL, CY, Thalidomide, CyA	Normalized	Survive
7	Furutera 2020 pat 1	PC	NS	CG, MN	PSL, TCZ	Complete remission	Survive
8	The present case	PC	Mild proteinuria	MN	PSL, TCZ	Complete remission	Survive

ATIN Acute tuburointerstitial nephritis, ARF Acute renal failure, CG Crescentic glomerulonephritis, CY Cyclophosphamide, CyA Cyclosporin A, HD Hemodialysis, HV Hyaline-vascular type, IN Interstitial nephritis, LN Lymph node, Mixed Mixed type, MN Membranous nephropathy, NA Not available, NS Nephrotic syndrome, pat Patient, PC Plasma cell type, PE Plasma exchange, PSL Prednisolone, R-CHOP rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone, RPGN Rapidly progressive glomerulonephritis, TCZ Tocilizumab

ISSN: 1471-2369